Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||₹30.30|
|52 Week High||₹16.60|
|52 Week Low||₹65.00|
|1 Month Change||-8.32%|
|3 Month Change||-1.46%|
|1 Year Change||64.67%|
|3 Year Change||218.61%|
|5 Year Change||294.53%|
|Change since IPO||109.69%|
Recent News & Updates
|500009||IN Pharmaceuticals||IN Market|
Return vs Industry: 500009 exceeded the Indian Pharmaceuticals industry which returned 20% over the past year.
Return vs Market: 500009 matched the Indian Market which returned 63.7% over the past year.
Stable Share Price: 500009 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 500009's weekly volatility (7%) has been stable over the past year.
About the Company
Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally. The company operates through Pharmaceuticals and Electronics segments. It offers products for oncology, infertility, and uro-gynaec areas under the Sarabhai house name; generic and veterinary products; antifungal active ingredient products; vitamin C coated products; and analytical, test, and measuring instruments, as well as supplies finished dosage forms and active pharmaceutical ingredients.
Ambalal Sarabhai Enterprises Fundamentals Summary
|500009 fundamental statistics|
Is 500009 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|500009 income statement (TTM)|
|Cost of Revenue||₹1.06b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||7.18|
|Net Profit Margin||30.63%|
How did 500009 perform over the long term?See historical performance and comparison
Is Ambalal Sarabhai Enterprises undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 500009's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 500009's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 500009 is good value based on its PE Ratio (4.2x) compared to the Indian Pharmaceuticals industry average (24.9x).
PE vs Market: 500009 is good value based on its PE Ratio (4.2x) compared to the Indian market (21.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 500009's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 500009's PB Ratio (3.1x) is in line with the IN Pharmaceuticals industry average.
How is Ambalal Sarabhai Enterprises forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ambalal Sarabhai Enterprises has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Ambalal Sarabhai Enterprises performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 500009 has a large one-off gain of ₹143.7M impacting its June 30 2021 financial results.
Growing Profit Margin: 500009's current net profit margins (30.6%) are higher than last year (11.1%).
Past Earnings Growth Analysis
Earnings Trend: 500009's earnings have grown significantly by 82.6% per year over the past 5 years.
Accelerating Growth: 500009's earnings growth over the past year (282.3%) exceeds its 5-year average (82.6% per year).
Earnings vs Industry: 500009 earnings growth over the past year (282.3%) exceeded the Pharmaceuticals industry 35.8%.
Return on Equity
High ROE: 500009's Return on Equity (74.5%) is considered outstanding.
How is Ambalal Sarabhai Enterprises's financial position?
Financial Position Analysis
Short Term Liabilities: 500009's short term assets (₹1.2B) do not cover its short term liabilities (₹1.3B).
Long Term Liabilities: 500009's short term assets (₹1.2B) exceed its long term liabilities (₹76.2M).
Debt to Equity History and Analysis
Debt Level: 500009's debt to equity ratio (35.5%) is considered satisfactory.
Reducing Debt: 500009's debt to equity ratio has reduced from 130.1% to 35.5% over the past 5 years.
Debt Coverage: 500009's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 500009's interest payments on its debt are not well covered by EBIT (1.1x coverage).
What is Ambalal Sarabhai Enterprises's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 500009's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 500009's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 500009's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 500009's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 500009's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ambalal Sarabhai Enterprises has no CEO, or we have no data on them.
Experienced Management: 500009's management team is considered experienced (2.5 years average tenure).
Experienced Board: 500009's board of directors are considered experienced (9.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ambalal Sarabhai Enterprises Limited's employee growth, exchange listings and data sources
- Name: Ambalal Sarabhai Enterprises Limited
- Ticker: 500009
- Exchange: BSE
- Founded: 1880
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹2.322b
- Shares outstanding: 76.63m
- Website: https://www.ase.life
Number of Employees
- Ambalal Sarabhai Enterprises Limited
- Shanti Sadan
- Mirzapur Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 18:04|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.